In the past week, URGN stock has gone down by -0.68%, with a monthly decline of -6.02% and a quarterly surge of 15.59%. The volatility ratio for the week is 5.28%, and the volatility levels for the last 30 days are 5.64% for UroGen Pharma Ltd The simple moving average for the last 20 days is 0.45% for URGN stock, with a simple moving average of 2.55% for the last 200 days.
Is It Worth Investing in UroGen Pharma Ltd (NASDAQ: URGN) Right Now?
Additionally, the 36-month beta value for URGN is 1.12. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for URGN is 38.12M and currently, short sellers hold a 16.00% ratio of that float. The average trading volume of URGN on August 22, 2024 was 668.42K shares.
URGN) stock’s latest price update
The stock of UroGen Pharma Ltd (NASDAQ: URGN) has increased by 3.46 when compared to last closing price of 14.87. Despite this, the company has experienced a -0.68% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-13 that UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone – Head, Investor Relations Liz Barrett – President and Chief Executive Officer Mark Schoenberg – Chief Medical Officer David Lin – Chief Commercial Officer Dong Kim – Chief Financial Officer Conference Call Participants Tara Bancroft – TD Cowen Raghuram Selvaraju – H.C.
Analysts’ Opinion of URGN
Jefferies, on the other hand, stated in their research note that they expect to see URGN reach a price target of $10, previously predicting the price at $35. The rating they have provided for URGN stocks is “Hold” according to the report published on February 08th, 2023.
Berenberg gave a rating of “Buy” to URGN, setting the target price at $20 in the report published on April 27th of the previous year.
URGN Trading at -3.88% from the 50-Day Moving Average
After a stumble in the market that brought URGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.46% of loss for the given period.
Volatility was left at 5.64%, however, over the last 30 days, the volatility rate increased by 5.28%, as shares sank -5.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.41% upper at present.
During the last 5 trading sessions, URGN rose by +0.06%, which changed the moving average for the period of 200-days by +33.97% in comparison to the 20-day moving average, which settled at $15.27. In addition, UroGen Pharma Ltd saw 2.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at URGN starting from Schoenberg Mark, who sale 5,153 shares at the price of $13.08 back on Jun 10 ’24. After this action, Schoenberg Mark now owns 144,284 shares of UroGen Pharma Ltd, valued at $67,401 using the latest closing price.
Schoenberg Mark, the Chief Medical Officer of UroGen Pharma Ltd, sale 12,000 shares at $14.05 during a trade that took place back on Mar 18 ’24, which means that Schoenberg Mark is holding 139,437 shares at $168,600 based on the most recent closing price.
Stock Fundamentals for URGN
Current profitability levels for the company are sitting at:
- -0.94 for the present operating margin
- 0.9 for the gross margin
The net margin for UroGen Pharma Ltd stands at -1.34. The total capital return value is set at -0.32.
Based on UroGen Pharma Ltd (URGN), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at -0.84. The debt to equity ratio resting at 3.25. The interest coverage ratio of the stock is -6.7.
Currently, EBITDA for the company is -63.83 million with net debt to EBITDA at 1.57. When we switch over and look at the enterprise to sales, we see a ratio of 6.2. The receivables turnover for the company is 4.88for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.15.
Conclusion
In conclusion, UroGen Pharma Ltd (URGN) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
